-
摘要: 急性髓系白血病(acute myeloid leukemia，AML)是一种高度异质性的血液系统恶性肿瘤，常规治疗以细胞毒药物化疗为主，但总体疗效不理想，5年生存率不到30%。近年来随着对AML发病机制及基因突变认识的逐渐深入，一系列新型分子靶向药物相继问世。这些药物明显改善了AML患者的预后，为AML患者提供更多的治疗选择。本文就分子靶向治疗在AML中的研究进展作一综述。Abstract: Acute myeloid leukemia(AML) is a highly heterogeneous hematologic malignancy. The conventional treatment of AML is cytotoxic chemotherapy. However, the overall survival of AML is not ideal and the 5-year survival rate is less than 30%. Recently, a series of novel molecular targeted drugs have been developed. These drugs have significantly improved the prognosis of patients with AML and provided more treatment options. This article reviews the progress of molecular targeted therapy in AML.
-
Key words:
- acute myeloid leukemia /
- targeted therapy /
- progress
-
-
[1] Sami SA, Darwish N, Barile A, et al. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy[J]. Curr Treat Options Oncol, 2020, 21(1): 3. doi: 10.1007/s11864-019-0694-6
[2] Hou JZ, Ye JC, Pu JJ, et al. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting[J]. J Hematol Oncol, 2021, 14(1): 66. doi: 10.1186/s13045-021-01077-3
[3] Fedorov K, Maiti A, Konopleva M. Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions[J]. Cancers(Basel), 2023, 15(8): 2312.
[4] Larson RA, Mandrekar SJ, Huebner LJ, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial[J]. Leukemia, 2021, 35(9): 2539-2551. doi: 10.1038/s41375-021-01179-4
[5] Murdock HM, Kim HT, Denlinger N, et al. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML[J]. Blood, 2022, 139(24): 3546-3557. doi: 10.1182/blood.2021014520
[6] Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with flt3-itd acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial[J]. Lancet Oncol, 2020, 21(9): 1201-1212. doi: 10.1016/S1470-2045(20)30455-1
[7] Swaminathan M, Kantarjian HM, Levis M, et al. A phase Ⅰ/Ⅱ study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Haematologica, 2021, 106(8): 2121-2130. doi: 10.3324/haematol.2020.263392
[8] Desikan SP, Daver N, DiNardo C, et al. Resistance to targeted therapies: delving into FLT3 and IDH[J]. Blood Cancer J, 2022, 12(6): 91. doi: 10.1038/s41408-022-00687-5
[9] Erba H, Montesinos P, Vrhovac R, et al. AML-029 Quizartinib Prolonged Overall Survival(OS)vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3-Internal Tandem Duplication Positive(FLT3-ITD+)Acute Myeloid Leukemia(AML)[J]. Clin Lymph Myelom Leuk, 2022, 22: S208-S209.
[10] Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML[J]. N Engl J Med, 2019, 381(18): 1728-1740. doi: 10.1056/NEJMoa1902688
[11] Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial[J]. Blood, 2022, 139(23): 3366-3375. doi: 10.1182/blood.2021011583
[12] Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy[J]. Blood, 2022, 140(17): 1845-1857. doi: 10.1182/blood.2021014586
[13] Ferng TT, Terada D, Ando M, et al. The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms[J]. Mol Cancer Ther, 2022, 21(5): 844-854. doi: 10.1158/1535-7163.MCT-21-0317
[14] Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm[J]. Blood Cancer J, 2021, 11(6): 107. doi: 10.1038/s41408-021-00497-1
[15] Thol F, Ganser A. Treatment of Relapsed Acute Myeloid Leukemia[J]. Curr Treat Options Oncol, 2020, 21(8): 66. doi: 10.1007/s11864-020-00765-5
[16] Wang J, Jin J, Yin Q, et al. Ivosidenib in Chinese patients(pts)with relapsed/refractory acute myeloid leukemia(R/R AML)with an IDH1 mutation: Results from a bridging registrational study[J]. Ann Oncol, 2021, 32: S773.
[17] Montesinos P, Recher C, Vives S, et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia[J]. N Engl J Med, 2022, 386(16): 1519-1531. doi: 10.1056/NEJMoa2117344
[18] de Botton S, Montesinos P, Schuh AC, et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial[J]. Blood, 2023, 141(2): 156-167. doi: 10.1182/blood.2021014901
[19] Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study[J]. Blood, 2021, 137(13): 1792-1803. doi: 10.1182/blood.2020007233
[20] Cortes JE, Esteve J, Bajel A, et al. Olutasidenib(FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia[J]. Blood, 2021, 138(Supplement 1): 698. doi: 10.1182/blood-2021-144905
[21] Heuser M, Palmisiano N, Mantzaris I, et al. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase Ⅰ study results[J]. Leukemia, 2020, 34(11): 2903-2913. doi: 10.1038/s41375-020-0996-5
[22] Cluzeau T, Loschi M, Fenaux P, et al. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia[J]. Int J Mol Sci, 2021, 22(18): 10105. doi: 10.3390/ijms221810105
[23] DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia[J]. N Engl J Med, 2020, 383(7): 617-629. doi: 10.1056/NEJMoa2012971
[24] Jonas BA, Wei AH, Recher C, et al. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia[J]. Am J Hematol, 2022, 97(8): E299-E303.
[25] 吴迪, 李秋柏. BCL-2抑制剂在急性髓性白血病临床应用新策略[J]. 临床血液学杂志, 2022, 35(5): 318-322. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.05.004
[26] Roboz GJ, Ravandi F, Wei AH, et al. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status[J]. Blood, 2022, 139(14): 2145-2155. doi: 10.1182/blood.2021013404
[27] Stomper J, Rotondo JC, Greve G, et al. Hypomethylating agents(HMA)for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies[J]. Leukemia, 2021, 35(7): 1873-1889. doi: 10.1038/s41375-021-01218-0
[28] Benjamin DN, O'Donovan TR, Laursen KB, et al. All-Trans-Retinoic Acid Combined With Valproic Acid Can Promote Differentiation in Myeloid Leukemia Cells by an Autophagy Dependent Mechanism[J]. Front Oncol, 2022, 12: 848517. doi: 10.3389/fonc.2022.848517
[29] Zavras PD, Shastri A, Goldfinger M, et al. Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions[J]. Clin Cancer Res, 2021, 27(24): 6653-6661. doi: 10.1158/1078-0432.CCR-21-2139
[30] Wieduwilt MJ, Pawlowska N, Thomas S, et al. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase Ⅰ Study Results[J]. Clin Cancer Res, 2019, 25(16): 4917-4923. doi: 10.1158/1078-0432.CCR-19-0171
[31] 金洁, 周一乐. 成人急性髓细胞白血病的诊断与治疗进展[J]. 临床血液学杂志, 2022, 35(5): 309-311, 317. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.05.002
[32] Sekeres MA, Schuster M, Joris M, et al. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes[J]. Ann Hematol, 2022, 101(8): 1689-1701. doi: 10.1007/s00277-022-04853-4
[33] Gallazzi M, Ucciero M, Faraci DG, et al. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes[J]. Int J Mol Sci, 2022, 23(14): 7542. doi: 10.3390/ijms23147542
[34] Li W, Wang F, Guo R, et al. Targeting macrophages in hematological malignancies: recent advances and future directions[J]. J Hematol Oncol, 2022, 15(1): 110. doi: 10.1186/s13045-022-01328-x
[35] Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia[J]. Blood, 2021, 137(6): 751-762. doi: 10.1182/blood.2020007732
-
计量
- 文章访问数: 606
- PDF下载数: 807
- 施引文献: 0
下载: